A pilot study at Beth Israel Deaconess Medical Center has demonstrated the feasibility of administering a modification of a concurrent biochemotherapy regimen , initially described by Legha et al , consisting of cisplatin , vinblastine , and dacarbazine ( CVD ) plus IL-2 and IFN-alpha in the cooperative group setting .
